# A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

> **NCT06826196** · PHASE1,PHASE2 · RECRUITING · sponsor: **Aldena Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Alopecia Areata (AA)

## Interventions

- **DRUG:** ALD-102 Solution
- **OTHER:** Placebo or Control

## Key facts

- **NCT ID:** NCT06826196
- **Lead sponsor:** Aldena Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826196, "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06826196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*